JP2016513658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513658A5 JP2016513658A5 JP2016502179A JP2016502179A JP2016513658A5 JP 2016513658 A5 JP2016513658 A5 JP 2016513658A5 JP 2016502179 A JP2016502179 A JP 2016502179A JP 2016502179 A JP2016502179 A JP 2016502179A JP 2016513658 A5 JP2016513658 A5 JP 2016513658A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- composition
- alphavirus
- concentration
- live
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 241000710929 Alphavirus Species 0.000 claims 18
- 241000700605 Viruses Species 0.000 claims 14
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 7
- 108010010803 Gelatin Proteins 0.000 claims 7
- 239000007995 HEPES buffer Substances 0.000 claims 7
- 239000008273 gelatin Substances 0.000 claims 7
- 229920000159 gelatin Polymers 0.000 claims 7
- 235000019322 gelatine Nutrition 0.000 claims 7
- 235000011852 gelatine desserts Nutrition 0.000 claims 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 5
- 229930006000 Sucrose Natural products 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 230000003612 virological effect Effects 0.000 claims 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 241001502567 Chikungunya virus Species 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 3
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 claims 3
- 201000005804 Eastern equine encephalitis Diseases 0.000 claims 3
- 206010014587 Encephalitis eastern equine Diseases 0.000 claims 3
- 206010014614 Encephalitis western equine Diseases 0.000 claims 3
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 241000710942 Ross River virus Species 0.000 claims 3
- 241000710961 Semliki Forest virus Species 0.000 claims 3
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 claims 3
- 201000005806 Western equine encephalitis Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 3
- 230000002238 attenuated effect Effects 0.000 claims 3
- 229930182830 galactose Natural products 0.000 claims 3
- 230000002779 inactivation Effects 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 201000009182 Chikungunya Diseases 0.000 claims 2
- 239000000463 material Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784122P | 2013-03-14 | 2013-03-14 | |
| US61/784,122 | 2013-03-14 | ||
| PCT/US2014/026570 WO2014151855A1 (en) | 2013-03-14 | 2014-03-13 | Compositions and methods for live, attenuated alphavirus formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018200754A Division JP6761015B2 (ja) | 2013-03-14 | 2018-10-25 | 弱毒生アルファウイルス製剤のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513658A JP2016513658A (ja) | 2016-05-16 |
| JP2016513658A5 true JP2016513658A5 (https=) | 2017-04-13 |
| JP6426695B2 JP6426695B2 (ja) | 2018-11-21 |
Family
ID=50489420
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502179A Expired - Fee Related JP6426695B2 (ja) | 2013-03-14 | 2014-03-13 | 弱毒生アルファウイルス製剤のための組成物および方法 |
| JP2018200754A Expired - Fee Related JP6761015B2 (ja) | 2013-03-14 | 2018-10-25 | 弱毒生アルファウイルス製剤のための組成物および方法 |
| JP2020148154A Withdrawn JP2020193231A (ja) | 2013-03-14 | 2020-09-03 | 弱毒生アルファウイルス製剤のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018200754A Expired - Fee Related JP6761015B2 (ja) | 2013-03-14 | 2018-10-25 | 弱毒生アルファウイルス製剤のための組成物および方法 |
| JP2020148154A Withdrawn JP2020193231A (ja) | 2013-03-14 | 2020-09-03 | 弱毒生アルファウイルス製剤のための組成物および方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10137186B2 (https=) |
| EP (2) | EP3603667A1 (https=) |
| JP (3) | JP6426695B2 (https=) |
| KR (1) | KR20160003662A (https=) |
| CN (2) | CN111729077A (https=) |
| AP (1) | AP2015008733A0 (https=) |
| AU (2) | AU2014236804B2 (https=) |
| BR (1) | BR112015023205A2 (https=) |
| CA (1) | CA2903711A1 (https=) |
| CR (1) | CR20150553A (https=) |
| DO (1) | DOP2015000226A (https=) |
| EC (1) | ECSP20007842A (https=) |
| MX (2) | MX361342B (https=) |
| MY (1) | MY178476A (https=) |
| NZ (1) | NZ631012A (https=) |
| PH (1) | PH12015502115B1 (https=) |
| SG (3) | SG11201507462QA (https=) |
| TW (2) | TW201900192A (https=) |
| WO (1) | WO2014151855A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2015008733A0 (en) * | 2013-03-14 | 2015-09-30 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
| WO2015097650A1 (en) | 2013-12-23 | 2015-07-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| KR20180135912A (ko) * | 2016-03-31 | 2018-12-21 | 다케다 백신즈 인코포레이티드 | 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법 |
| NL2022538B1 (en) * | 2019-02-08 | 2020-08-19 | Academisch Ziekenhuis Groningen | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof. |
| CA3174826A1 (en) * | 2021-01-19 | 2022-07-28 | Katsuro HAGIWARA | Virus stabilizer, gelatin hydrolysate for virus stabilizer, and virus-containing composition |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| RU2035508C1 (ru) * | 1991-08-16 | 1995-05-20 | Институт органической химии СО РАН | Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей |
| US5545555A (en) * | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| AU4594996A (en) * | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6458560B1 (en) * | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
| CA2337905A1 (en) * | 1998-07-30 | 2000-03-02 | Johns Hopkins University School Of Medicine | Targeted alphavirus and alphaviral vectors |
| US6869907B2 (en) * | 2000-05-02 | 2005-03-22 | Pentax Corporation | Color-image-forming medium |
| FR2814957B1 (fr) * | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
| CA2469623C (en) * | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| WO2003087327A2 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| EP1701738B1 (en) | 2003-12-17 | 2015-03-11 | Wyeth LLC | Method for producing storage stable RSV compositions |
| CN101516395B (zh) * | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| DK2099485T3 (en) * | 2006-11-03 | 2018-05-22 | Alphavax Inc | Alphavirus and alphavirus replica particle formulations and associated methods |
| MX2009004862A (es) | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| WO2009014774A1 (en) | 2007-04-06 | 2009-01-29 | Inviragen, Inc. | Methods and compositions for live attenuated viruses |
| CA2698392C (en) | 2007-09-04 | 2019-12-03 | Baoming Jiang | Thermal inactivation of rotavirus |
| PL2198007T3 (pl) | 2007-09-14 | 2018-03-30 | Sanofi Pasteur Biologics, Llc | Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile |
| KR101668849B1 (ko) | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
| SI2759306T1 (sl) | 2008-12-09 | 2016-05-31 | Coley Pharmaceutical Group, Inc. | Imunostimulacijski oligonukleotidi |
| EP2519539A4 (en) | 2009-12-28 | 2013-11-13 | Ligocyte Pharmaceuticals Inc | METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES |
| CA2801151A1 (en) * | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| AP2015008733A0 (en) | 2013-03-14 | 2015-09-30 | Takeda Vaccines Inc | Compositions and methods for live, attenuated alphavirus formulations |
-
2014
- 2014-03-13 AP AP2015008733A patent/AP2015008733A0/xx unknown
- 2014-03-13 SG SG11201507462QA patent/SG11201507462QA/en unknown
- 2014-03-13 MX MX2015012894A patent/MX361342B/es active IP Right Grant
- 2014-03-13 NZ NZ631012A patent/NZ631012A/en not_active IP Right Cessation
- 2014-03-13 JP JP2016502179A patent/JP6426695B2/ja not_active Expired - Fee Related
- 2014-03-13 CA CA2903711A patent/CA2903711A1/en not_active Abandoned
- 2014-03-13 KR KR1020157029550A patent/KR20160003662A/ko not_active Ceased
- 2014-03-13 CN CN202010573138.6A patent/CN111729077A/zh active Pending
- 2014-03-13 SG SG10201909051Q patent/SG10201909051QA/en unknown
- 2014-03-13 CN CN201480018785.3A patent/CN105377293B/zh not_active Expired - Fee Related
- 2014-03-13 EP EP19172758.5A patent/EP3603667A1/en not_active Withdrawn
- 2014-03-13 SG SG10201801459SA patent/SG10201801459SA/en unknown
- 2014-03-13 AU AU2014236804A patent/AU2014236804B2/en not_active Ceased
- 2014-03-13 WO PCT/US2014/026570 patent/WO2014151855A1/en not_active Ceased
- 2014-03-13 BR BR112015023205A patent/BR112015023205A2/pt not_active IP Right Cessation
- 2014-03-13 MY MYPI2015002316A patent/MY178476A/en unknown
- 2014-03-13 US US14/209,921 patent/US10137186B2/en not_active Expired - Fee Related
- 2014-03-13 EP EP14717940.2A patent/EP2968515B1/en active Active
- 2014-03-13 TW TW107130863A patent/TW201900192A/zh unknown
- 2014-03-13 TW TW103109097A patent/TWI649087B/zh not_active IP Right Cessation
-
2015
- 2015-09-09 DO DO2015000226A patent/DOP2015000226A/es unknown
- 2015-09-14 PH PH12015502115A patent/PH12015502115B1/en unknown
- 2015-09-14 MX MX2018014977A patent/MX2018014977A/es unknown
- 2015-10-14 CR CR20150553A patent/CR20150553A/es unknown
-
2018
- 2018-10-01 AU AU2018236897A patent/AU2018236897B2/en not_active Ceased
- 2018-10-12 US US16/159,221 patent/US10806781B2/en not_active Expired - Fee Related
- 2018-10-25 JP JP2018200754A patent/JP6761015B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-31 EC ECSENADI20207842A patent/ECSP20007842A/es unknown
- 2020-09-03 JP JP2020148154A patent/JP2020193231A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513658A5 (https=) | ||
| PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
| EP4275705A3 (en) | Pancreatitis treatment | |
| PH12015502230A1 (en) | Novel viral replication inhibitors | |
| WO2014158811A8 (en) | Newcastle disease viruses and uses thereof | |
| NZ780244A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
| WO2017156511A8 (en) | Live attenuated zika virus vaccine | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| PH12017500320B1 (en) | Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis | |
| ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| JP2017019841A5 (https=) | ||
| WO2015126129A3 (ko) | C형 간염 바이러스의 게놈 복제의 선택적 저해 활성을 갖는 레스베라트롤 다량체 및 이의 용도 | |
| EP3556373C0 (en) | COMPOSITION COMPRISING SEA CUCUMBER EXTRACT AS AN EFFECTIVE INGREDIENT FOR PREVENTING AND TREATING BRUCH'S MEMBRANE DYSFUNCTION DISEASE | |
| AR101932A1 (es) | Agente con propiedades antivirales para prevenir o tratar peces expuestos a un virus de la familia birnaviridae | |
| Jiggins | Research data supporting" Parallel and costly changes to cellular immunity underlie the evolution of parasitoid resistance in three Drosophila species" | |
| WO2015120127A3 (en) | Treating flavivirus infections with amodiaquine and derivatives thereof | |
| Naves Neto et al. | Odontogenic myxoma in children: case report | |
| 刘夕强 | Vasopressin analogue terlipressin exerts its hepatoprotective effects via the V1R signaling pathway | |
| WARITAY | Design and Implementation of the Social Safety Net (Cash Transfer) Project in Sierra Leone | |
| Xinfeng | Still Reaping Dividends | |
| Middeldorp | Thyrotoxicosis: 6 case reports | |
| Dávila et al. | Injury Prevention Through Population-Level Interventions | |
| KIM et al. | Successful Non-operative Management of Intra-abdominal Hemorrhage in Two Patients with Hemophilia A | |
| Hedegaard | QuickStats |